A phase II study of allogeneic hematopoetic stem cell transplant for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine and melphalan
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 May 2018
At a glance
- Drugs Fludarabine (Primary) ; Ibritumomab tiuxetan (Primary) ; Melphalan (Primary) ; Rituximab; Sirolimus; Tacrolimus; Tacrolimus
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Graft-versus-host disease; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 07 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Mar 2019.
- 07 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Mar 2019.
- 06 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.